Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Chemopreventive efficacy of the cyclooxygenase-2 (Cox-2) inhibitor, celecoxib, is predicted by adenoma expression of Cox-2 and 15-PGDH.

Wang J, Cho NL, Zauber AG, Hsu M, Dawson D, Srivastava A, Mitchell-Richards KA, Markowitz SD, Bertagnolli MM.

Cancer Epidemiol Biomarkers Prev. 2018 May 16. pii: cebp.0573.2017. doi: 10.1158/1055-9965.EPI-17-0573. [Epub ahead of print]

PMID:
29769213
2.

Reply.

Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB.

Gastroenterology. 2018 May 8. pii: S0016-5085(18)34536-0. doi: 10.1053/j.gastro.2018.05.017. [Epub ahead of print] No abstract available.

PMID:
29750906
3.

Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations.

Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB; Cystic Fibrosis Colorectal Cancer Screening Task Force.

Gastroenterology. 2018 Feb;154(3):736-745.e14. doi: 10.1053/j.gastro.2017.12.012. Epub 2017 Dec 29.

PMID:
29289528
4.

Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.

Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, Lowenfels AB, Lansdorp-Vogelaar I.

Gastroenterology. 2017 Dec 27. pii: S0016-5085(17)36715-X. doi: 10.1053/j.gastro.2017.12.011. [Epub ahead of print]

PMID:
29288655
5.

Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries.

Peterse EFP, Meester RGS, Gini A, Doubeni CA, Anderson DS, Berger FG, Zauber AG, Lansdorp-Vogelaar I.

Health Aff (Millwood). 2017 Dec;36(12):2151-2159. doi: 10.1377/hlthaff.2017.0228.

PMID:
29200350
6.

Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.

Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, Alagoz O, Stout N, Lansdorp-Vogelaar I, Corley DA, Tosteson ANA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):158-164. doi: 10.1158/1055-9965.EPI-17-0378. Epub 2017 Nov 17.

PMID:
29150480
7.

Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.

Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, Lowenfels AB, Lansdorp-Vogelaar I.

Gastroenterology. 2018 Feb;154(3):556-567.e18. doi: 10.1053/j.gastro.2017.10.036. Epub 2017 Nov 2.

PMID:
29102616
8.

Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests: A Systematic Review.

Selby K, Baumgartner C, Levin TR, Doubeni CA, Zauber AG, Schottinger J, Jensen CD, Lee JK, Corley DA.

Ann Intern Med. 2017 Oct 17;167(8):565-575. doi: 10.7326/M17-1361. Epub 2017 Oct 10. Review.

PMID:
29049756
9.

A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening.

Shapiro JA, Bobo JK, Church TR, Rex DK, Chovnick G, Thompson TD, Zauber AG, Lieberman D, Levin TR, Joseph DA, Nadel MR.

Am J Gastroenterol. 2017 Nov;112(11):1728-1735. doi: 10.1038/ajg.2017.285. Epub 2017 Oct 10.

PMID:
29016558
10.

Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer.

Naber SK, Kuntz KM, Henrikson NB, Williams MS, Calonge N, Goddard KAB, Zallen DT, Ganiats TG, Webber EM, Janssens ACJW, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I.

Gastroenterology. 2018 Jan;154(1):105-116.e20. doi: 10.1053/j.gastro.2017.09.021. Epub 2017 Sep 28.

PMID:
28964749
11.

Accurate Identification of Colonoscopy Quality and Polyp Findings Using Natural Language Processing.

Lee JK, Jensen CD, Levin TR, Zauber AG, Doubeni CA, Zhao WK, Corley DA.

J Clin Gastroenterol. 2017 Sep 12. doi: 10.1097/MCG.0000000000000929. [Epub ahead of print]

PMID:
28906424
12.

Impact of adenoma detection on the benefit of faecal testing vs. colonoscopy for colorectal cancer.

Meester RGS, Doubeni CA, Zauber AG, van Ballegooijen M, Corley DA, Lansdorp-Vogelaar I.

Int J Cancer. 2017 Dec 1;141(11):2359-2367. doi: 10.1002/ijc.30933. Epub 2017 Aug 31.

PMID:
28815573
13.

Can post-polypectomy surveillance be less intensive?

Winawer SJ, Zauber AG.

Lancet Oncol. 2017 Jun;18(6):707-709. doi: 10.1016/S1470-2045(17)30305-4. Epub 2017 Apr 28. No abstract available.

14.

Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis.

Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Schottinger JE, Marks AR, Zhao WK, Ghai NR, Lee AT, Contreras R, Quesenberry CP, Fireman BH, Levin TR.

JAMA. 2017 Apr 25;317(16):1631-1641. doi: 10.1001/jama.2017.3634.

PMID:
28444278
15.

Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study.

Mendelsohn RB, Winawer SJ, Jammula A, Mills G, Jordan P, O'Brien MJ, Close GM, Dorfman M, Church TR, Mandelson MT, Allen J, Feld A, Kauff ND, Morgan GA, Kumar JMR, Serrano V, Bayuga-Miller S, Fischer SE, Kuk D, Zauber AG.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1469-1470. doi: 10.1016/j.cgh.2017.04.014. Epub 2017 Apr 15. No abstract available.

PMID:
28419856
16.

Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy.

McFerran E, O'Mahony JF, Fallis R, McVicar D, Zauber AG, Kee F.

Epidemiol Rev. 2017 Jan 1;39(1):148-160. doi: 10.1093/epirev/mxx002. Review.

PMID:
28402402
17.

Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.

Goede SL, Rabeneck L, van Ballegooijen M, Zauber AG, Paszat LF, Hoch JS, Yong JH, Kroep S, Tinmouth J, Lansdorp-Vogelaar I.

PLoS One. 2017 Mar 15;12(3):e0172864. doi: 10.1371/journal.pone.0172864. eCollection 2017.

18.

Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature.

Doubeni CA, Jensen CD, Fedewa SA, Quinn VP, Zauber AG, Schottinger JE, Corley DA, Levin TR.

J Am Board Fam Med. 2016 11/12;29(6):672-681. doi: 10.3122/jabfm.2016.06.160060.

19.

Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps.

Marcus PM, Pashayan N, Church TR, Doria-Rose VP, Gould MK, Hubbard RA, Marrone M, Miglioretti DL, Pharoah PD, Pinsky PF, Rendle KA, Robbins HA, Roberts MC, Rolland B, Schiffman M, Tiro JA, Zauber AG, Winn DM, Khoury MJ.

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1449-1455. Epub 2016 Aug 9.

20.

Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study.

Doubeni CA, Corley DA, Quinn VP, Jensen CD, Zauber AG, Goodman M, Johnson JR, Mehta SJ, Becerra TA, Zhao WK, Schottinger J, Doria-Rose VP, Levin TR, Weiss NS, Fletcher RH.

Gut. 2018 Feb;67(2):291-298. doi: 10.1136/gutjnl-2016-312712. Epub 2016 Oct 12.

21.

Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System.

Mehta SJ, Jensen CD, Quinn VP, Schottinger JE, Zauber AG, Meester R, Laiyemo AO, Fedewa S, Goodman M, Fletcher RH, Levin TR, Corley DA, Doubeni CA.

J Gen Intern Med. 2016 Nov;31(11):1323-1330. Epub 2016 Jul 13.

22.

Endoscopist fatigue estimates and colonoscopic adenoma detection in a large community-based setting.

Lee A, Jensen CD, Marks AR, Zhao WK, Doubeni CA, Zauber AG, Quinn VP, Levin TR, Corley DA.

Gastrointest Endosc. 2017 Mar;85(3):601-610.e2. doi: 10.1016/j.gie.2016.09.033. Epub 2016 Oct 1.

23.

Breast cancer screening initiation after turning 40 years of age within the PROSPR consortium.

Beaber EF, Tosteson AN, Haas JS, Onega T, Sprague BL, Weaver DL, McCarthy AM, Doubeni CA, Quinn VP, Skinner CS, Zauber AG, Barlow WE.

Breast Cancer Res Treat. 2016 Nov;160(2):323-331. Epub 2016 Sep 24.

24.

A restricted look at CRC screening: not considering annual stool testing as an option.

Kuntz KM, Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Berger BM, Levin B.

Am J Manag Care. 2016 Jul 1;22(7):e270-4. No abstract available.

25.

Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.

Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, Johanson C, Fischer SE, Lansdorp-Vogelaar I, Kuntz KM.

JAMA. 2016 Jun 21;315(23):2595-609. doi: 10.1001/jama.2016.6828.

26.

Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A state-of-the-science review.

Lowery JT, Ahnen DJ, Schroy PC 3rd, Hampel H, Baxter N, Boland CR, Burt RW, Butterly L, Doerr M, Doroshenk M, Feero WG, Henrikson N, Ladabaum U, Lieberman D, McFarland EG, Peterson SK, Raymond M, Samadder NJ, Syngal S, Weber TK, Zauber AG, Smith R.

Cancer. 2016 Sep 1;122(17):2633-45. doi: 10.1002/cncr.30080. Epub 2016 Jun 3. Review. Erratum in: Cancer. 2017 Oct 1;123(19):3857.

27.

Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial.

Bretthauer M, Kaminski MF, Løberg M, Zauber AG, Regula J, Kuipers EJ, Hernán MA, McFadden E, Sunde A, Kalager M, Dekker E, Lansdorp-Vogelaar I, Garborg K, Rupinski M, Spaander MC, Bugajski M, Høie O, Stefansson T, Hoff G, Adami HO; Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group.

JAMA Intern Med. 2016 Jul 1;176(7):894-902. doi: 10.1001/jamainternmed.2016.0960.

28.

Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test.

Meester RG, Zauber AG, Doubeni CA, Jensen CD, Quinn VP, Helfand M, Dominitz JA, Levin TR, Corley DA, Lansdorp-Vogelaar I.

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1445-1451.e8. doi: 10.1016/j.cgh.2016.05.017. Epub 2016 May 19. Erratum in: Clin Gastroenterol Hepatol. 2018 May;16(5):787.

29.

Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity.

Joseph DA, Meester RG, Zauber AG, Manninen DL, Winges L, Dong FB, Peaker B, van Ballegooijen M.

Cancer. 2016 Aug 15;122(16):2479-86. doi: 10.1002/cncr.30070. Epub 2016 May 20. Erratum in: Cancer. 2017 Oct 1;123(19):3857.

30.

Rationale and design of the European Polyp Surveillance (EPoS) trials.

Jover R, Bretthauer M, Dekker E, Holme Ø, Kaminski MF, Løberg M, Zauber AG, Hernán MA, Lansdorp-Vogelaar I, Sunde A, McFadden E, Castells A, Regula J, Quintero E, Pellisé M, Senore C, Kalager M, Dinis-Ribeiro M, Emilsson L, Ransohoff DF, Hoff G, Adami HO.

Endoscopy. 2016 Jun;48(6):571-8. doi: 10.1055/s-0042-104116. Epub 2016 Apr 4.

31.

Colorectal Cancer Health Disparities and the Role of US Law and Health Policy.

Doubeni CA, Corley DA, Zauber AG.

Gastroenterology. 2016 May;150(5):1052-1055. doi: 10.1053/j.gastro.2016.03.012. Epub 2016 Mar 24. No abstract available.

32.

Colorectal Cancer.

Rabeneck L, Horton S, Zauber AG, Earle C.

In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: Disease Control Priorities, Third Edition (Volume 3). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2015 Nov 1. Chapter 6.

33.

Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.

Jensen CD, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Zhao WK, Marks AR, Schottinger JE, Ghai NR, Lee AT, Contreras R, Klabunde CN, Quesenberry CP, Levin TR, Mysliwiec PA.

Ann Intern Med. 2016 Apr 5;164(7):456-63. doi: 10.7326/M15-0983. Epub 2016 Jan 26.

34.

Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications.

Rutter CM, Knudsen AB, Marsh TL, Doria-Rose VP, Johnson E, Pabiniak C, Kuntz KM, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I.

Med Decis Making. 2016 Jul;36(5):604-14. doi: 10.1177/0272989X15622642. Epub 2016 Jan 8.

35.

Cancer Models and Real-world Data: Better Together.

Kim JJ, Tosteson AN, Zauber AG, Sprague BL, Stout NK, Alagoz O, Trentham-Dietz A, Armstrong K, Pruitt SL, Rutter CM; Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium.

J Natl Cancer Inst. 2015 Nov 3;108(2). pii: djv316. doi: 10.1093/jnci/djv316. Print 2016 Feb.

36.

Systematic meta-analyses and field synopsis of genetic association studies in colorectal adenomas.

Montazeri Z, Theodoratou E, Nyiraneza C, Timofeeva M, Chen W, Svinti V, Sivakumaran S, Gresham G, Cubitt L, Carvajal-Carmona L, Bertagnolli MM, Zauber AG, Tomlinson I, Farrington SM, Dunlop MG, Campbell H, Little J.

Int J Epidemiol. 2016 Feb;45(1):186-205. doi: 10.1093/ije/dyv185. Epub 2015 Oct 7. Review.

37.

Factors influencing variation in physician adenoma detection rates: a theory-based approach for performance improvement.

Atkins L, Hunkeler EM, Jensen CD, Michie S, Lee JK, Doubeni CA, Zauber AG, Levin TR, Quinn VP, Corley DA.

Gastrointest Endosc. 2016 Mar;83(3):617-26.e2. doi: 10.1016/j.gie.2015.08.075. Epub 2015 Sep 11.

38.

Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness.

van Hees F, Saini SD, Lansdorp-Vogelaar I, Vijan S, Meester RG, de Koning HJ, Zauber AG, van Ballegooijen M.

Gastroenterology. 2015 Nov;149(6):1425-37. doi: 10.1053/j.gastro.2015.07.042. Epub 2015 Aug 4.

39.

Observational methods to assess the effectiveness of screening colonoscopy in reducing right colon cancer mortality risk: SCOLAR.

Goodman M, Fletcher RH, Doria-Rose VP, Jensen CD, Zebrowski AM, Becerra TA, Quinn VP, Zauber AG, Corley DA, Doubeni CA.

J Comp Eff Res. 2015 Nov;4(6):541-51. doi: 10.2217/cer.15.39. Epub 2015 Jul 23.

40.

Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model.

Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Jensen CD, van der Meulen MP, Levin TR, Quinn VP, Schottinger JE, Zauber AG, Corley DA, van Ballegooijen M.

JAMA. 2015 Jun 16;313(23):2349-58. doi: 10.1001/jama.2015.6251.

41.

Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening.

Goede SL, Kuntz KM, van Ballegooijen M, Knudsen AB, Lansdorp-Vogelaar I, Tangka FK, Howard DH, Chin J, Zauber AG, Seeff LC.

Med Care. 2015 Jul;53(7):630-8. doi: 10.1097/MLR.0000000000000380.

42.

The value of models in informing resource allocation in colorectal cancer screening: the case of The Netherlands.

van Hees F, Zauber AG, van Veldhuizen H, Heijnen ML, Penning C, de Koning HJ, van Ballegooijen M, Lansdorp-Vogelaar I.

Gut. 2015 Dec;64(12):1985-97. doi: 10.1136/gutjnl-2015-309316. Epub 2015 Jun 10. Review.

43.

Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening.

Beaber EF, Kim JJ, Schapira MM, Tosteson AN, Zauber AG, Geiger AM, Kamineni A, Weaver DL, Tiro JA; Population-based Research Optimizing Screening through Personalized Regimens Consortium.

J Natl Cancer Inst. 2015 May 7;107(6):djv120. doi: 10.1093/jnci/djv120. Print 2015 Jun.

44.

A Comparison of the Cost-Effectiveness of Fecal Occult Blood Tests with Different Test Characteristics in the Context of Annual Screening in the Medicare Population [Internet].

van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Aug 9.

45.

Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer [Internet].

Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Dec 20.

46.

Cost-Effectiveness of CT Colonography to Screen for Colorectal Cancer [Internet].

Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Savarino JE, van Ballegooijen M, Kuntz KM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Jan 22.

47.

Development and validation of a clinical score for predicting risk of adenoma at screening colonoscopy.

Shaukat A, Church TR, Shanley R, Kauff ND, O'Brien MJ, Mills GM, Jordan PA, Allen JA, Kim A, Feld AD, Zauber AG, Winawer SJ.

Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):913-20. doi: 10.1158/1055-9965.EPI-14-1321. Epub 2015 Mar 23.

48.

Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018.

Meester RG, Doubeni CA, Zauber AG, Goede SL, Levin TR, Corley DA, Jemal A, Lansdorp-Vogelaar I.

Cancer. 2015 Jul 1;121(13):2281-5. doi: 10.1002/cncr.29336. Epub 2015 Mar 12.

49.

The impact of screening on colorectal cancer mortality and incidence: has it really made a difference?

Zauber AG.

Dig Dis Sci. 2015 Mar;60(3):681-91. doi: 10.1007/s10620-015-3600-5. Epub 2015 Mar 5. Review.

50.

Colorectal cancer deaths attributable to nonuse of screening in the United States.

Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Goede SL, Levin TR, Quinn VP, Ballegooijen Mv, Corley DA, Zauber AG.

Ann Epidemiol. 2015 Mar;25(3):208-213.e1. doi: 10.1016/j.annepidem.2014.11.011. Epub 2014 Dec 5.

Supplemental Content

Loading ...
Support Center